Proteovista LLC

Proteovista LLC, a woman-owned small business based in Madison, Wisconsin, develops synthetic biology tools and aptamer technologies for the National Institutes of Health as a prime recipient on federal research grants, with recent work focused on cost-effective biosynthetic gene cluster and viral genome synthesis platforms. The company operates primarily as a grant recipient (92% of recent awards by count) rather than a federal contractor, and competes under small business set-asides on both contract and grant vehicles.

Proteovista's capability portfolio centers on DNA microarray-based synthesis methods, peptide nucleic acid (PNA) error correction, and aptamer development for immunological research. The company's representative work includes a $600 thousand firm-fixed-price contract with the National Institute of Allergy and Infectious Diseases (NIAID) awarded in August 2021 for development of aptamers to recognize Nod-like receptors in zebrafish, which completed in January 2025; a $306,151 project grant from the National Institute of General Medical Sciences (NIGMS, CFDA 93.859) awarded in June 2026 for development of ClusterBuild, a novel platform for cost-effective synthesis of large biosynthetic gene clusters up to 100 kilobases; and a March 2023 project grant from the National Human Genome Research Institute for development of GenomeBuild, a platform for rapid, inexpensive synthesis of customizable viral genomes using DNA microarray technology. Proteovista also serves as a sub-recipient on a University of Wisconsin System grant from the National Cancer Institute, where the company's scientists conduct protein binding-affinity and specificity experiments using microarray technology to support cancer-focused transcription-factor research.

Customer concentration sits entirely within the National Institutes of Health. NIH institutes and component divisions account for 100% of documented awards: the National Cancer Institute (4 awards), unspecified NIH programs (3 awards), NIAID (1 award at $600 thousand), NHGRI (1 award), and HHS programs outside NIH (1 award). The sole contract award in the source data is the NIAID aptamer contract; all other awards are project grants. Award activity is episodic rather than recurring — the company received two awards in 2019 and one each in 2021, 2022, 2023, and 2026, with combined potential value of $600 thousand but combined obligated dollars of $4.5 million, indicating substantial year-over-year obligations against grant awards whose face value represents early-stage allocations. One award completes in the next twenty-four months, creating recompete exposure limited to that single grant.

Service Contract Inventory captures $165 thousand in SCI-reportable invoiced revenue in FY2022 across 0.5 FTEs on a prime contract at a median government-paid rate of $169.59 per hour, with no SCI activity recorded in FY2023 or FY2024. SCI is a partial view covering only service contracts above the $150,000 reporting threshold; Proteovista's core work is delivered through research grants, which fall outside SCI's scope and represent the company's primary federal revenue stream. The company does not operate as a subcontractor on SCI-reportable prime contracts and has not named subcontractors in available grant sub-award filings.